2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 769

Damage in Takayasu‘s Arteritis Is Associated with Age at Symptom-onset, Disease-duration and Corticosteroid Dose but Not Relapse in Routine Follow-up
Abstract Number: 1356

DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis
Abstract Number: 2435

Data Driven Prediction Lymphoma Model and 10-year Overall Survival Rates of a Large Harmonized Cohort of Patients with Primary Sjögren’s Syndrome Associated Lymphomas
Abstract Number: 2857

Decision Tree Analysis to Identify Inflammatory Arthritis Patient Subgroups with Different Levels of Treatment Persistence with First-Line Subcutaneous TNF-alpha Inhibitors
Abstract Number: 2731

Decomposition Analysis of Spending and Price Trends for Biologic Anti-Rheumatic Drugs in Medicare and Medicaid
Abstract Number: 644

Decreased HVEM Expression in Lupus Patients and Impact of HVEM Knockout Mouse Model of Lupus Suggest a Role for BTLA Signaling in Disease Pathogenesis
Abstract Number: 476

Decreased Muscle Mass, a Novel Predicting Indicator for One-year Radiographic Progression in Rheumatoid Arthritis: A Real-world Cohort Study
Abstract Number: 1561

Decreased Nocturnal Blood Pressure Dipping in Patients with Systemic Lupus Erythematosus: Association with Markers of Inflammation
Abstract Number: 1159

Deep Learning Social Media Analysis Demonstrated Gender-Specific Disparity in Side Effects from Rheumatoid Medications
Abstract Number: 2561

Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells
Abstract Number: 116

Defective EZH2 Expression Attenuates Treg Differentiation in Rheumatoid Arthritis
Abstract Number: 1789

Defibrotide Inhibits Antiphospholipid Antibody-Mediated NET Release and Endothelial Cell Activation
Abstract Number: 1358

Defining Minimal Clinically Important Changes for the Patient Activity Scale-II
Abstract Number: 1592

Defining the SLE-Associated Pulmonary Arterial Hypertension Phenotype
Abstract Number: 299

Definition of New Ultrasound Enthesophytes Score: Application in a Consecutive Series of IBD Patients

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].